Huberman Lab Clips | How Do Ozempic, Mounjaro & Other GPL-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman @HubermanLabClips | Uploaded September 2024 | Updated October 2024, 2 days ago.
Dr. Zachary Knight and Dr. Andrew Huberman discuss the development of GLP-1 drugs like Ozempic for diabetes and weight loss, examining their historical origins, biological mechanisms, and impact on appetite and metabolism.

Dr. Zachary Knight is a professor of physiology at the University of California, San Francisco (UCSF), and Howard Hughes Medical Institute (HHMI) investigator. Dr. Andrew Huberman is a tenured professor of neurobiology and ophthalmology at Stanford University School of Medicine and host of the Huberman Lab podcast.

Watch the full episode: youtu.be/C5KpIXjpzdY
Show notes: hubermanlab.com/episode/dr-zachary-knight-the-science-of-hunger-medications-to-combat-obesity

Timestamps
00:00 Introduction to Weight Loss Challenges
00:06 The Discovery of GLP-1 & Its Origins
01:35 Understanding the Incretin Effect
02:58 The Role of GLP-1 in Diabetes Treatment
04:39 Challenges & Innovations in GLP-1 Drug Development
05:52 Breakthroughs in GLP-1 Drugs for Weight Loss
10:47 Mechanisms of GLP-1 Drugs in the Brain
13:39 Conclusion & Further Insights

#HubermanLab #Science #GLP1

Disclaimer & Disclosures: hubermanlab.com/disclaimer